Member Info for Thompi

Shame there isn’t a cure, PL75, for getting rid of Thorn’s latest reincarnation as Teabag and his malicious posts.

What I genuinely don’t understand is why people repeatedly post about a share they’re not invested in. I thought we’d finally seen the back of Thorn and his record of 41 posts in 24 hours. That would have been a bit odd even for someone who held the shares, but for someone with no investment at all it’s just bizarre.

I really have to bite my tongue because he really winds me up. I tried filtering him last year but I could still see the replies to him.

Teabag/Thorn are you invested in Avacta? And if not then what is your motivation for posting on this board?

Touk, the reference was not from December 2025. If you read my post properly you will see that I clearly said it was from the prelims presentation - which was last month.

I included the link - and I will attach it again for you. It was approximately 50 minutes into the presentation.

https://www.investormeetcompany.com/meetings/preliminary-results-88

Sorry about the formatting - LSE goes off on a wobbly sometimes.

Ben, I think I can answer Touk’s question to you about the NDA reference.

It was approximately 50 minutes into the prelims presentation.

“It’s also important to note that we do also have substantive conversations with a number of partners that are under confidential nondisclosure agreements across different assets. These discussions, I would

describe them as constructive. They are progressing. But given the NDAs that are in place, it

wouldn't be appropriate for me to speculate on any kind of status beyond saying that we do

have a clear business development plan that we are executing”.

https://www.investormeetcompany.com/meetings/preliminary-results-88

I was going for alliteration but for some reason LSE allows twat but not to-sser. Having put up with Thorn for years, please the god of LSE remove his reincarnation - Teabag.

teabag=thorn=******=transparent=twat.

Tim, I still look book at the good old days (somtime earlier this year) when Thorn was in his pomp(ous) twat best. Will we ever see the like again (take note Teabag) with his 41 posts in one day? An absolute fud-fest classic. Some record - I don’t think it will ever be beaten even by the combined “to me to you” tag team.

I’m almost feeling nostalgic…

Nice little video clip of Alex Spira from SD posted by Sandy on X.

ADC’s have dominated, understandably the headlines, but they have side effects which also limits their MTD. AVA6103 offers differentiation - “a unique entity and moeity” were the words he used, if I have remembered correctly.

https://x.com/sandyradders/status/2059685941367709923?s=12

Thanks BV & Opti for the Science Day feedback - it’s very much appreciated.

For some reason LSE seems to remove any capital letters if you use a word they don’t like. I should have just used Thorn the twat…

yes, there are some tells with teabag/thorn - like the questions.

but you have to pump up the volume with the posts. thornogson set the bar high - will the record 41 posts in twenty-four hours ever be beaten? i doubt it - the ******.

Thanks BV for pointing that out - it’s easy to let our enthusiasm run away with us sometimes, but you are right that the “new site” was already referenced back in March.

Interesting though that, according to comments from the Science Day shared on X, the company plans to expand to around 8 sites for Phase 1a and potentially up to 20 for the next stage.

Unlikely Wyn that RH could have flipped his placing. Under UK MAR, the PDMR disclosure threshold is €5,000 aggregate transactions within a calendar year. RH, as a NED, falls within those rules.

We have had no announcements indicating he has sold.

https://www.fca.org.uk/publications/newsletters/primary-market-bulletin-issue-no-30

Good post Craig.

I don’t think RH would have shelled out £500k in the recent placing if he genuinely believed, to quote Rich, that the “setup screams further downside as more CLN amortizations hit”.

That is a meaningful investment, not just a token gesture.

Morning 54retiresoon, I think you may be recalling an answer Chris gave during last September’s interims presentation:

“Great question. Our pre|CISION platform has a couple of key differences compared to these other peptide drug conjugates. We often get asked this by institutional investors.

So let me take Bicycle first. The Bicycle peptide drug conjugates don’t use a cleavable technology. That’s one big difference between the pre|CISION platform and the Bicycle platform. The Bicycle peptide is designed to direct the payload to the tumour. We think the reason pre|CISION and this tumour-specific cleavage is so critical, in our mind, is borne out in the clinic. We see a 10-fold greater concentration of active payload in our biopsy samples compared with the published data from the Bicycle peptide. So while they see 10x concentration, we’re seeing a median 100-fold concentration.

I’ve mentioned this before, but it was really during a board meeting, when I saw those data for the first time, that I thought to myself: I’d really like to have a full-time role. I was just a non-exec at that point.

We also think these data allow us to leverage much more potent payloads. That’s why we can be bold and move into the exatecan programme.”

LongBull it feels a little speculative to suggest that the absence of Trodelvy may imply unfavourable data.

Perhaps the simpler explanation is that Avacta wanted a comparison against the current gold-standard/top-selling Topo-1 ADC franchise -= Daiichi’s DXd platform - because that is the scientific and commercial benchmark most people in oncology would immediately recognise.

As you suggest, another reason may simply be budget and resource allocation. Running multiple comparator studies is neither quick nor cheap.

Tbh, I don’t really see the absence of Trodelvy as “the more telling detail”. Avacta have by now developed an intimate knowledge of exatecan, which is itself a very broad and increasingly important payload class in oncology.

Hi Wilson - yes - Cumulus is referring to the data in figure 10 on the poster.

https://x.com/sandyradders/status/2047569740466401445?s=61&t=BBb2UcjLDTXOFIzJM-vM6A

Courtesy of Stonks yesterday and Sandy this morning on X.

“ In this model, at least, we’re actually doing rather better than Enhertu… We seem to be doing quite well… this is quite an exciting piece of data, I think” (David Jones)

Classic understatement from DJ.

It took me a few listens of the presentation and I probably have still missed some of the nuances. Roll on Science Day.

https://x.com/sandyradders/status/2047586879445340480?s=61&t=BBb2UcjLDTXOFIzJM-vM6A

Morning BV,

Just for interest’s sake, this is what Chris said in the recent RX interview on potential additional AVA6103 indications.

“ER-positive breast cancer, non-small cell lung cancer are two of the next ones on that magic list that we developed with Tempus. So there’s a lot - Topo I is just, it’s a very widely active mechanism in oncology, and so there’s a number of places that we can take this one. I always mention colorectal - it’s a very heterogeneous disease, but I do think that there’s probably a nice subset of colorectal that it would work in as well.”

Video clip courtesy of X.

https://x.com/sandyradders/status/2046273479968739375?s=61&t=BBb2UcjLDTXOFIzJM-vM6A